A Phase 3, 14-Day, Double-blind, Randomized, Placebo-Controlled, Multicenter Study of the Efficacy and Safety of Tolperisone in Subjects With Pain Due to Acute Back Muscle Spasm
Latest Information Update: 24 Mar 2022
At a glance
- Drugs Tolperisone (Primary)
- Indications Back pain; Spasm
- Focus Registrational; Therapeutic Use
- Acronyms RESUME-1
- Sponsors Neurana Pharmaceuticals
- 22 Mar 2022 Primary endpoint has not been met. (Numerical rating scale (NRS))
- 22 Mar 2022 Results presented in a Neurana Pharmaceuticals media release.
- 21 Mar 2022 Status changed from active, no longer recruiting to completed.